immunocore-logo-2018
Immunocore Reports First Quarter 2021 Financial Results
May 12, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Immunocore1.png
Immunocore announces key appointments to management and Board
February 16, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore1.png
Immunocore Announces Pricing of Upsized Initial Public Offering
February 04, 2021 22:07 ET | Immunocore Limited
PRESS RELEASE Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc...
Immunocore1.png
Immunocore announces closing of $75.0 Million Series C round
January 11, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...
Immunocore1.png
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
December 03, 2020 06:01 ET | Immunocore Limited
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
Immunocore1.png
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore1.png
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 02:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore1.png
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
May 06, 2020 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...
Immunocore1.png
Immunocore Secures $130 Million Series B Financing
March 02, 2020 07:00 ET | Immunocore Limited
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
logo.jpg
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
November 19, 2018 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...